Bristol Myers Squibb Company
NEWS
Bristol Myers Squibb announced positive data from two separate Phase III clinical trials of its checkpoint inhibitor Opdivo (nivolumab).
Eliquis generic was approved by FDA to prevent strokes, blood clots etc. But there were some legal issues which recently got stave off. Know more about it here.
August is a busy month on the U.S. Food and Drug Administration (FDA)’s calendar. Here’s a look at this week’s schedule.
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
This morning, BMS said Zeposia achieved positive topline results in the Phase III True North clinical study in patients with moderate to severe ulcerative colitis.
The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.
Numerous biopharmaceutical companies and researchers are presenting research and clinical trial results, and many have been announcing their plans for several weeks.
Bristol Myers Squibb is doing its best to claim market share in the checkpoint inhibitor space and over the past month, the company is pushing its way forward with a pair of regulatory approvals in lung cancer.
This morning, the two companies announced a global collaboration that will harness the power of Repare’s CRISPR-enabled platform to discover the next generation of precision oncology medicines.
JOBS
IN THE PRESS